18 September 2020 - NICE has published draft guidance recommending Bristol-Myers Squibb's Opdivo (nivolumab) as a second-line treatment option for patients with squamous or non-squamous non-small-cell lung cancer.

First-line of treatment for locally advanced stages of the disease is currently either chemotherapy or a PD-1 or PD-L1 inhibitor; Opdivo has been endorsed for patient groups treated with chemotherapy only.

NICE noted that clinical trial evidence suggests both non-squamous and squamous patient groups experienced an improvement in overall survival when treated with the immunotherapy, compared with patients treated with docetaxel, a current second-line treatment option for the disease.

Read Pharma Times article